Angel Pharmaceuticals receives IND approval for Phase 1/1b Inhibitor in China
pharmafile | October 28, 2021 | News story | Business Services |
Angel Pharmaceuticals has received approval for their IND application, from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), to initiate a Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818, for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.
This approval was announced by a partner of Angel Pharmaceuticals, clinical-stage biopharmaceutical company Corvus Pharmaceuticals.
Corvus co-founded Angel Pharma to develop its pipeline in China, and holds an equity stake of 49.7% in the company. Angel Pharma licensed the rights from Corvus to develop, manufacture, and commercialise the inhibitor CPI-818 in greater China, and is responsible for all expenses related to its development in China.
Angel Pharma is developing a pipeline of preceisely targeted, investigational medicines for cancer, autoimmune, infectious, and other serious diseases in China. It was launched through a collaboration iwith US based Corvus Pharmaceuticals, and investments from investors in China.
Richard A. Miller, MD, co-founder, president and CEO of Corvus, said: “Our strategy to partner with Angel Pharma to accelerate global development of our products is advancing. There is a higher incidence and prevalence of T-cell lymphomas in China, and a significant need for new treatment options.
“The Angel Pharma team has been efficiently moving the development process forward and has partnered with top lymphoma clinical experts. CPI-818 is the only clinical stage ITK-inhibitor in China, and is positioned to become a potential novel therapy for T-cell lymphoma and more broadly for autoimmune diseases, which we plan to explore over time.”